|
業務類別
|
Biotechnology |
|
業務概覽
|
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States. |
| 公司地址
| 238 Main Street, Cambridge, MA, USA, 02142 |
| 電話號碼
| +1 857 327-8775 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.beamtx.com |
| 員工數量
| 511 |
| Mr. Sravan K. Emany |
Chief Financial Officer |
美元 575.00K |
17/04/2026 |
| Ms. Bethany J. Cavanagh |
Principal Accounting Officer, Treasurer and Senior Vice President, Finance |
-- |
24/02/2026 |
| Mr. John Evans |
Chief Executive Office and Director |
美元 755.00K |
17/04/2026 |
| Dr. Giuseppe Ciaramella, PhD |
President |
美元 668.00K |
17/04/2026 |
| Dr. Christine Bellon, PhD |
Chief Legal Officer and Secretary |
美元 510.50K |
17/04/2026 |
| Dr. Amy Simon, M.D. |
Chief Medical Officer |
美元 550.00K |
17/04/2026 |
|
|
| Mr. Graham K. Cooper |
Independent Director |
17/04/2026 |
| Dr. John M. Maraganore,PhD |
Independent Director |
17/04/2026 |
| Ms. Christi Shaw |
Independent Director |
17/04/2026 |
| Dr. Mark C. Fishman, M.D. |
Lead Independent Director |
17/04/2026 |
| Mr. Chirfi Guindo |
Independent Director |
17/04/2026 |
| Ms. Kathleen E. Walsh |
Independent Director |
17/04/2026 |
| Mr. John Evans |
Chief Executive Office and Director |
17/04/2026 |
|
|
|
|
